The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
14-Nov-16
$748 million
Target:
Peacock Foods
Acquiror:
Greencore Group plc
Advised Greencore Group plc, a leading international manufacturer of convenience foods based in Ireland, on the proposed acquisition of Peacock Foods, a manufacturing partner for consumer packaged goods companies in the US.
14-Nov-16
$346 million
Target:
Etrion Corporation's Italian solar photovoltaic platform
Acquiror:
Ultor S.p.A.
Advised Etrion Corporation, a solar independent power producer and developer, on the sale of its 60MW Italian solar photovoltaic platform to Ultor S.p.A. (a joint venture owned equally by Enel Green Power S.p.A. and F2i Fondi Italiani per le infrastrutture) for an Enterprise Value of €323m
14-Nov-16
$NA
Target:
Lion’s Australian Premium Wine Business – Fine Wine Partners
Acquiror:
Accolade Wines
Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Australian wine business Fine Wine Partners to Accolade Wines, a portfolio company of CHAMP Private Equity
03-Nov-16
$NA
Target:
Fragrance Resources Group
Acquiror:
International Flavors & Fragrances Inc.
Advised IFF, one of the world’s largest flavors and fragrances businesses, on the acquisition of Fragrance Resources Group, a family-owned fragrance company headquartered in Switzerland
03-Nov-16
$3.3 billion
Target:
Metaldyne Performance Group, Inc.
Acquiror:
American Axle & Manufacturing Holdings, Inc.
Advised American Axle & Manufacturing Holdings, Inc., a leading manufacturer of driveline and drivetrain systems and related components and metal-formed products, on the acquisition of Metaldyne Performance Group, Inc., a provider of highly-engineered lightweight components for use in powertrain and suspension applications for the global light, commercial and industrial vehicle markets
02-Nov-16
$NA
Target:
IAC/InterActiveCorp
Advised the Special Committee of the Board of Directors of IAC/InterActiveCorp, a leading media and internet company, on the potential creation of a new class of non-voting common stock
17-Oct-16
$1.4 billion
Target:
Save-A-Lot
Acquiror:
Affiliate of Onex Corporation
Advised SUPERVALU, Inc., one of the largest grocery wholesalers and retailers in the U.S., on the sale of its Save-A-Lot business, a leading hard-discount grocery retailer in the U.S., to an affiliate of Onex Corporation
13-Oct-16
$NA
Target:
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
04-Oct-16
$223 million
Target:
U.S. rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the U.S. rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
04-Oct-16
$32.0 billion
Target:
Texas Competitive Electric Holdings and its subsidiaries
Advised Texas Competitive Electric Holdings, Texas’ largest power generator and competitive retail electricity provider, and its subsidiaries at the direction of its independent director in connection with its and Energy Future Holdings’ Chapter 11 proceedings
29-Sep-16
$628 million
Target:
van Gansewinkel Groep BV
Acquiror:
Shanks Group plc
Advised Shanks Group plc, a leading international waste to product business, on the proposed merger with van Gansewinkel Groep BV, one of the leading waste management service providers, recyclers and suppliers of high-quality secondary raw materials in the Benelux region.
07-Sep-16
$NA
Target:
TEGNA, Inc.
Advised TEGNA, Inc., a major broadcasting and digital marketing services company, on the spin-off of Cars.com and the creation of two independent publicly traded companies: one focused on television broadcasting and one focused on the online automotive marketplace.
18-Aug-16
$3.2 billion
Target:
Valves & Controls Business of Pentair
Acquiror:
Emerson
Advised Emerson, a diversified global technology and industrial company, on the acquisition of the Valves & Controls business of Pentair
09-Aug-16
$NA
Target:
Bionomics Limited
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
08-Aug-16
$1.5 billion
Target:
Whistler Blackcomb Holdings Inc.
Acquiror:
Vail Resorts, Inc.
Advised Whistler Blackcomb Holdings Inc., a 75% owner and operator of the largest and most visited mountain resort in North America, on its sale to Vail Resorts, Inc.
08-Aug-16
$87 million
Target:
Aquasana, Inc.
Acquiror:
A. O. Smith Corporation
Advised A. O. Smith Corporation, a leading manufacturer of residential and commercial water heaters and boilers, on the acquisition of Aquasana, a premium water treatment company, from L Catterton
28-Jul-16
$80 million
Target:
BioD, LLC
Acquiror:
Derma Sciences, Inc.
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
08-Jul-16
$555 million
Target:
New Enterprise Stone & Lime Co., Inc.
Advised New Enterprise Stone & Lime Co., Inc. on $555 million of secured financings, including a new $450 million senior secured term loan and substantial amendments to its existing $105 million ABL revolver
28-Jun-16
$NA
Target:
U.S. rights to an authorized generic version of Adderall XR
Acquiror:
Prasco Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to an authorized generic version of Adderall XR
28-Jun-16
$652 million
Target:
U.S. rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 42 generic products
27-Jun-16
$156 million
Target:
ReachLocal
Acquiror:
Gannett
Served as independent financial advisor to the Board of Directors of Gannett in connection with its acquisition of ReachLocal
21-Jun-16
$586 million
Target:
U.S. rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
20-Jun-16
$NA
Target:
U.S. rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 2 generic drug products to Zydus Cadila